These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 36570647)

  • 1. Lifestyle habits to prevent the development of benign prostatic hyperplasia: Analysis of Japanese nationwide datasets.
    Nagakura Y; Hayashi M; Kajioka S
    Prostate Int; 2022 Dec; 10(4):200-206. PubMed ID: 36570647
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Analysis of Japanese nationwide health datasets: association between lifestyle habits and prevalence of neuropathic pain and fibromyalgia with reference to dementia-related diseases and Parkinson's disease.
    Nagakura Y; Hayashi M; Kajioka S
    Scand J Pain; 2023 Oct; 23(4):662-669. PubMed ID: 37439280
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Triglyceride to high-density lipoprotein cholesterol ratio and total cholesterol to high-density lipoprotein cholesterol ratio and risk of benign prostatic hyperplasia in Chinese male subjects.
    Zhu C; Wu J; Wu Y; Guo W; Lu J; Zhu W; Li X; Xu N; Zhang Q
    Front Nutr; 2022; 9():999995. PubMed ID: 36263299
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term dutasteride therapy in men with benign prostatic hyperplasia alters glucose and lipid profiles and increases severity of erectile dysfunction.
    Traish A; Haider KS; Doros G; Haider A
    Horm Mol Biol Clin Investig; 2017 Jun; 30(3):. PubMed ID: 28632494
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical, anthropometric, metabolic and insulin profile of men with fast annual growth rates of benign prostatic hyperplasia.
    Hammarsten J; Högstedt B
    Blood Press; 1999; 8(1):29-36. PubMed ID: 10412880
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Benign prostatic hyperplasia: the opposite effects of alcohol and coffee intake.
    Gass R
    BJU Int; 2002 Nov; 90(7):649-54. PubMed ID: 12410741
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The impacts of metabolic syndrome and lifestyle on the prevalence of benign prostatic hyperplasia requiring treatment: historical cohort study of 130 454 men.
    Yoo S; Oh S; Park J; Cho SY; Cho MC; Jeong H; Son H
    BJU Int; 2019 Jan; 123(1):140-148. PubMed ID: 30125452
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Improvements in benign prostatic hyperplasia-specific quality of life with dutasteride, the novel dual 5alpha-reductase inhibitor.
    O'Leary MP; Roehrborn C; Andriole G; Nickel C; Boyle P; Höfner K
    BJU Int; 2003 Aug; 92(3):262-6. PubMed ID: 12887480
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Influence of baseline variables on changes in International Prostate Symptom Score after combined therapy with dutasteride plus tamsulosin or either monotherapy in patients with benign prostatic hyperplasia and lower urinary tract symptoms: 4-year results of the CombAT study.
    Roehrborn CG; Barkin J; Tubaro A; Emberton M; Wilson TH; Brotherton BJ; Castro R
    BJU Int; 2014 Apr; 113(4):623-35. PubMed ID: 24127818
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of metabolic syndrome-related factors on the development of benign prostatic hyperplasia and lower urinary tract symptoms in Asian population.
    Park JS; Koo KC; Kim HK; Chung BH; Lee KS
    Medicine (Baltimore); 2019 Oct; 98(42):e17635. PubMed ID: 31626149
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical outcomes after combined therapy with dutasteride plus tamsulosin or either monotherapy in men with benign prostatic hyperplasia (BPH) by baseline characteristics: 4-year results from the randomized, double-blind Combination of Avodart and Tamsulosin (CombAT) trial.
    Roehrborn CG; Barkin J; Siami P; Tubaro A; Wilson TH; Morrill BB; Gagnier RP
    BJU Int; 2011 Mar; 107(6):946-54. PubMed ID: 21332630
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of α1-Blockers for Lower Urinary Tract Symptoms and Sleep Disorders in Patients with Benign Prostatic Hyperplasia.
    Sakuma T; Sato K; Nagane Y; Mochida J; Sugimoto S; Ichinose T; Yamaguchi K; Uchiyama M; Takahashi S
    Low Urin Tract Symptoms; 2010 Sep; 2(2):119-22. PubMed ID: 26676294
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Optimal high-density lipoprotein cholesterol level for decreasing benign prostatic hyperplasia in men not taking statin medication: A historical cohort study.
    Yoo S; Oh S; Suh J; Park J; Cho MC; Jeong H; Won S; Son H
    Prostate; 2020 May; 80(7):570-576. PubMed ID: 32196725
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dutasteride improves outcomes of benign prostatic hyperplasia when evaluated for prostate cancer risk reduction: secondary analysis of the REduction by DUtasteride of prostate Cancer Events (REDUCE) trial.
    Roehrborn CG; Nickel JC; Andriole GL; Gagnier RP; Black L; Wilson TH; Rittmaster RS
    Urology; 2011 Sep; 78(3):641-6. PubMed ID: 21764428
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Linh Phu Khang Tue Tinh inhibited prostate proliferation in rats induced benign prostatic hyperplasia by testosterone propionate.
    Minh TD; Thanh Ha TN; Duy TN; Hoang NN; PhamTien D; Thai HP; Thi HN; Thi Lan PD; Quoc BP; Ivkin DY; Povydysh MN; Cong BN; Krasnova MV
    J Ethnopharmacol; 2021 Oct; 279():114388. PubMed ID: 34224813
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of a fixed-dose combination of dutasteride and tamsulosin treatment (Duodart(®) ) compared with watchful waiting with initiation of tamsulosin therapy if symptoms do not improve, both provided with lifestyle advice, in the management of treatment-naïve men with moderately symptomatic benign prostatic hyperplasia: 2-year CONDUCT study results.
    Roehrborn CG; Oyarzabal Perez I; Roos EP; Calomfirescu N; Brotherton B; Wang F; Palacios JM; Vasylyev A; Manyak MJ
    BJU Int; 2015 Sep; 116(3):450-9. PubMed ID: 25565364
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost effectiveness comparison of dutasteride and finasteride in patients with benign prostatic hyperplasia--The Markov model based on data from Montenegro.
    Dabanović V; Kostić M; Janković S
    Vojnosanit Pregl; 2016 Jan; 73(1):26-33. PubMed ID: 26964381
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Real-world data and treatment patterns of patients with lower urinary tract symptoms due to benign prostatic hyperplasia in Germany: an observational study using health insurance claims data.
    Miernik A; Fritzsche J; Libutzki B; Malka V; Kilemnik I; Mohebbi D; May M; Gratzke C; Suarez-Ibarrola R
    World J Urol; 2021 Dec; 39(12):4381-4388. PubMed ID: 34292368
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oxidised low-density lipoprotein, a possible distinguishing lipid profile biomolecule between prostate cancer and benign prostatic hyperplasia.
    Asare GA; Owusu-Boateng E; Asiedu B; Amoah BY; Essendoh E; Otoo RY
    Andrologia; 2019 Sep; 51(8):e13321. PubMed ID: 31145504
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rates of prostate surgery and acute urinary retention for benign prostatic hyperplasia in men treated with dutasteride or finasteride.
    Kuiper JG; Bezemer ID; Driessen MT; Vasylyev A; Roehrborn CG; Penning-van Beest FJ; Herings RM
    BMC Urol; 2016 Aug; 16(1):53. PubMed ID: 27580700
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.